Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 146 | 2.220 |
Why?
|
| Coronary Disease | 9 | 2015 | 51 | 1.640 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 55 | 1.420 |
Why?
|
| Cisplatin | 2 | 2023 | 61 | 1.380 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 324 | 1.360 |
Why?
|
| Secondary Prevention | 5 | 2020 | 51 | 1.260 |
Why?
|
| Cardiology | 5 | 2021 | 45 | 1.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 245 | 1.180 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 6 | 1.090 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 551 | 1.060 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.830 |
Why?
|
| Aniline Compounds | 2 | 2020 | 35 | 0.820 |
Why?
|
| Heart Failure | 7 | 2021 | 149 | 0.760 |
Why?
|
| Exercise Test | 3 | 2018 | 121 | 0.740 |
Why?
|
| Carboplatin | 1 | 2021 | 26 | 0.710 |
Why?
|
| Benzimidazoles | 1 | 2021 | 9 | 0.710 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 6 | 0.710 |
Why?
|
| Paclitaxel | 1 | 2021 | 51 | 0.710 |
Why?
|
| Standard of Care | 1 | 2020 | 13 | 0.700 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 240 | 0.680 |
Why?
|
| Humans | 38 | 2023 | 27214 | 0.660 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 8 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 16 | 0.640 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 15 | 0.590 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 1 | 0.590 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.590 |
Why?
|
| Life Style | 3 | 2019 | 186 | 0.580 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 37 | 0.570 |
Why?
|
| Mutation | 1 | 2019 | 352 | 0.570 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 202 | 0.560 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.550 |
Why?
|
| Apoptosis | 2 | 2022 | 211 | 0.550 |
Why?
|
| Taxoids | 1 | 2017 | 11 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 261 | 0.540 |
Why?
|
| ErbB Receptors | 3 | 2023 | 55 | 0.520 |
Why?
|
| Cell Proliferation | 1 | 2017 | 182 | 0.510 |
Why?
|
| Neoplasms | 1 | 2018 | 242 | 0.470 |
Why?
|
| Aged | 19 | 2023 | 9113 | 0.470 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 130 | 0.440 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 44 | 0.440 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 23 | 0.430 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 40 | 0.420 |
Why?
|
| Middle Aged | 16 | 2021 | 9057 | 0.420 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 11 | 0.400 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 132 | 0.400 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 411 | 0.400 |
Why?
|
| Male | 18 | 2023 | 14852 | 0.370 |
Why?
|
| Depression | 2 | 2015 | 446 | 0.360 |
Why?
|
| Critical Pathways | 1 | 2011 | 20 | 0.360 |
Why?
|
| Program Evaluation | 3 | 2017 | 117 | 0.350 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 19 | 0.350 |
Why?
|
| Female | 17 | 2021 | 15308 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 309 | 0.340 |
Why?
|
| Chest Pain | 1 | 2009 | 20 | 0.320 |
Why?
|
| Prognosis | 4 | 2021 | 804 | 0.320 |
Why?
|
| Mass Screening | 1 | 2011 | 174 | 0.320 |
Why?
|
| Australia | 8 | 2021 | 42 | 0.310 |
Why?
|
| Smartphone | 2 | 2021 | 15 | 0.310 |
Why?
|
| Models, Statistical | 1 | 2009 | 127 | 0.310 |
Why?
|
| Medication Adherence | 1 | 2009 | 52 | 0.310 |
Why?
|
| Exercise Therapy | 2 | 2021 | 91 | 0.290 |
Why?
|
| Risk Factors | 9 | 2019 | 2336 | 0.290 |
Why?
|
| Young Adult | 4 | 2021 | 2029 | 0.270 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.260 |
Why?
|
| Quality of Life | 4 | 2021 | 630 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 47 | 0.230 |
Why?
|
| Adult | 7 | 2021 | 7938 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 36 | 0.210 |
Why?
|
| Cetuximab | 1 | 2023 | 6 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 34 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2018 | 1784 | 0.210 |
Why?
|
| Counseling | 2 | 2017 | 41 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.190 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 40 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 65 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4842 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2021 | 37 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2019 | 630 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 172 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 123 | 0.170 |
Why?
|
| Comorbidity | 4 | 2021 | 488 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 49 | 0.160 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3547 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 6 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 55 | 0.160 |
Why?
|
| Walking Speed | 1 | 2019 | 42 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Diastole | 1 | 2019 | 31 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 35 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 19 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 36 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 50 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 9 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3525 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 68 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 173 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 16 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 478 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2019 | 76 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 14 | 0.150 |
Why?
|
| Pharynx | 1 | 2018 | 12 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 561 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 88 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 92 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 39 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 82 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 243 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 83 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 34 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 24 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 452 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 209 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 129 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 448 | 0.130 |
Why?
|
| Health Behavior | 3 | 2021 | 160 | 0.130 |
Why?
|
| Blotting, Western | 1 | 2017 | 148 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 462 | 0.130 |
Why?
|
| United States | 3 | 2018 | 2076 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 26 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 150 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 207 | 0.120 |
Why?
|
| Calcium | 1 | 2017 | 369 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2015 | 175 | 0.110 |
Why?
|
| New Zealand | 3 | 2020 | 11 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 162 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 60 | 0.090 |
Why?
|
| Family Practice | 1 | 2009 | 15 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 5 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 42 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 30 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 18 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 27 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 26 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 51 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 97 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 98 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 33 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 55 | 0.080 |
Why?
|
| Prevalence | 1 | 2009 | 458 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 16 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 28 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 763 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1438 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 63 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 344 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 23 | 0.060 |
Why?
|
| Immobilization | 1 | 2023 | 13 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 9 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 21 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 26 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 45 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 52 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 61 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 36 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 8 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 4 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 11 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 14 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 321 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 218 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 415 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 144 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 297 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 92 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 19 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 667 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 74 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 147 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 141 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 110 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 159 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 36 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 21 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 467 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 408 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 126 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 261 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 216 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 104 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 80 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 13 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 776 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 101 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1802 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 589 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 893 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 321 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 156 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 194 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1903 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 27 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 36 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 24 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 58 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 214 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 17 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 24 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 33 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 116 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 111 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 26 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 57 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 139 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 257 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 331 | 0.010 |
Why?
|
| Hypertension | 1 | 2002 | 194 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 165 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 309 | 0.010 |
Why?
|